OCGN Stock Forecast: Ocugen, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Ocugen, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 43 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Ocugen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (84): Analysts have, on balance, been raising their forecasts.
Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
OCGN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OCGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $10 → $9.50 |
| 27 May 2026 | Canaccord Genuity | Maintains | Buy | $12 → $11 |
| 25 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 17 Mar 2026 | Canaccord Genuity | Initiates | Buy | — |
| 11 Mar 2026 | Oppenheimer | Initiates | Outperform | — |
| 5 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 20 Jan 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Sept 2025 | Chardan Capital | Maintains | Buy | — |
| 4 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | Chardan Capital | Maintains | Buy | — |
| 24 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 May 2025 | Chardan Capital | Maintains | Buy | — |
| 12 May 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 6 Mar 2025 | Chardan Capital | Maintains | Buy | — |
| 6 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Feb 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Feb 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 23 Jan 2025 | Chardan Capital | Maintains | Buy | — |
| 13 Jan 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for OCGN.
This page is one stock. Monday covers all of them.
OCGN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
OCGN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Ocugen, Inc. returned −30.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OCGN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 56.2×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 4% of US stocks
- Revenue growth (YoY)
- 11.4%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 57% of US stocks
- Return on equity
- —
- Return on assets
- −52.1%
- Dividend yield
- —
Higher than 8% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Ocugen, Inc. has a market value of $248.6M and an enterprise value of $252.9M.
Revenue in the twelve months to 30 June 2026: $4.6M. The latest quarter grew 8.4% year on year.
Net income over the same four quarters: −$81.8M, a −1786.3% net margin.
Diluted earnings per share, trailing twelve months: −$0.25.
Free cash flow in the twelve months to 30 June 2026: −$61.0M.
Ocugen, Inc. employs 116 people — $39K of revenue per employee.
Data provided by Twelve Data
OCGN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at OCGN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Ocugen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about OCGN
What is the OCGN stock price forecast for 2026-2027?
The median 12-month analyst price target for Ocugen, Inc. is $11, with estimates ranging from $8 to $22. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is OCGN stock a buy right now?
Of the 6 analysts covering Ocugen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Ocugen, Inc. 43 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank OCGN?
As at 21 Nov 2026, Ocugen, Inc. ranks 43 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).
Will OCGN stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $11, and Ticker Nerd's factor model ranks Ocugen, Inc. 43 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the OCGN stock forecast for 2030?
No analyst covering Ocugen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OCGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $22 over the next 12 months.
How has OCGN stock performed over the past year?
Ocugen, Inc. returned -30.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Ocugen, Inc. do?
Ocugen, Inc. is a biotechnology company focused on developing gene and cell therapies, biologics, and vaccines designed to address serious and underserved medical conditions. Its current work spans ophthalmology, immunology, and infectious disease, with research programs targeting inherited retinal disorders, blindness caused by retinal degeneration, and other conditions involving vision loss.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on developing gene and cell therapies, biologics, and vaccines designed to address serious and underserved medical conditions. Its current work spans ophthalmology, immunology, and infectious disease, with research programs targeting inherited retinal disorders, blindness caused by retinal degeneration, and other conditions involving vision loss. The company also develops cellular therapies intended to support tissue repair and restore function, including approaches focused on cartilage and joint health. Ocugen, Inc. combines biotechnology research, clinical development, and potential commercialization activities to advance innovative treatments from laboratory concepts toward patient care. Its role in the financial market reflects the characteristics of a specialized biopharmaceutical business, where value is linked to scientific platforms, therapeutic development programs, regulatory progress, and the potential medical applications of its pipeline. The company serves the broader healthcare and life sciences sectors through its focus on novel treatments and vaccine technologies.
CEO Dr. Shankar Musunuri M.B.A., Ph.D. · 116 employees · United States · https://www.ocugen.com